Clinical TrialAug 3, 2026, 08:33 AM
Cadrenal Therapeutics focuses CAD-1005 on $1B+ CSA-AKI market
AI Summary
Cadrenal Therapeutics is consolidating its multi-indication strategy for CAD-1005, focusing on both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This intensified focus on CSA-AKI follows a competitor's recent Phase 3 failure, opening a $1 billion+ market opportunity for CAD-1005. The company highlighted compelling Phase 2 data for CAD-1005, showing over 25% reduction in thrombotic events and a renal-protective baseline. Cadrenal is actively seeking strategic partnerships for its Phase 3-ready asset.
Key Highlights
- CAD-1005 targets $1 billion+ U.S. CSA-AKI market opportunity.
- Competitor's late-stage Phase 3 trial for CSA-AKI failed due to lack of efficacy.
- CAD-1005 Phase 2 data showed >25% absolute reduction in thrombotic events.
- CAD-1005 demonstrated a favorable safety and renal-protective baseline.
- Company actively pursuing strategic partnerships for Phase 3-ready CAD-1005.
- CAD-1005 has Orphan Drug and Fast Track designations from the FDA.
Price Impact
More from CVKD